Display Settings:

Format

Send to:

Choose Destination
    Br J Cancer. 2010 Jan 5;102(1):162-4. Epub 2009 Dec 1.

    PTEN status in advanced colorectal cancer treated with cetuximab.

    Source

    Medical Oncology Unit, University Hospital, Parma 43100, Italy. francescanegri2@hotmail.com

    Abstract

    BACKGROUND:

    Loss of phosphatase and tensin homologue deleted in chromosome 10 (PTEN) function in advanced colorectal cancer (CRC) may represent one of the resistance mechanisms to cetuximab by interfering with the epidermal growth factor receptor signal transduction pathway.

    METHODS:

    PTEN expression tested by indirect immunofluorescence was evaluated both on primary (n=43) and on metastatic (n=24) sites in CRC patients treated with cetuximab.

    RESULTS:

    The loss of PTEN expression tested on metastatic sites was negatively associated with response (100% progressive disease (PD) in PTEN-negative cases vs 30% PD in PTEN-positive cases; P<0.05), PFS (0.8 vs 8.2 months; P<0.001) and OS (2.9 vs 14.2 months; P<0.001).

    CONCLUSION:

    A potential role of PTEN in the anti-tumour activity of cetuximab could be hypothesised.

    PMID:
    19953097
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2813733
    Free PMC Article

    Images from this publication.See all images (1) Free text

    Figure 1

    MeSH Terms, Substances

    MeSH Terms

    Substances

      Supplemental Content

      Icon for Nature Publishing Group Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk